LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a target name.
REQUEST A FREE TRIAL
Pipeline
Deals
Financings
Articles
BioCentury
|
Sep 22, 2023
Data Byte
Data comp: two IgA nephropathy therapies aiming for full approval
Two drugs received accelerated approval for IgA nephropathy: one has met its confirmatory endpoint, the other is moving ahead despite miss
Read More
BioCentury
|
Sep 18, 2023
Product Development
Data comp: four hypertension candidates advancing in the clinic
Idorsia’s aprocitentan under review, while Mineralys and AZ prepare for Phase III trials and Alnylam runs two more Phase II studies
Read More
BioCentury
|
Oct 16, 2020
Product Development
Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to
Drug development for heart failure is picking up, with five clinical readouts from five mechansims expected in the next year
Read More
BioCentury
|
Aug 29, 2019
Company News
Aug. 29 Company Quick Takes: EC approves Tecentriq for breast cancer, Giapreza for hypotension; plus Innovent reports Tyvyt sales
Read More
BioCentury
|
Jul 27, 2018
Clinical News
Reata reports retained benefit in Phase II CKD trial
Read More
BioCentury
|
Jul 23, 2018
Clinical News
Reata gains on retained benefit in CKD trial, proposes follow-on
Read More
BioCentury
|
May 11, 2018
Company News
La Jolla in $125M royalty financing for Giapreza
Read More
BioCentury
|
May 10, 2018
Financial News
La Jolla in $125M royalty financing for Giapreza
Read More
BioCentury
|
Mar 16, 2018
Financial News
La Jolla prices $100.3M follow-on
Read More
BioCentury
|
Mar 15, 2018
Financial News
La Jolla prices $100.3M follow-on
Read More
Items per page:
10
1 - 10 of 282